ONL Therapeutics’ $46.9 Million Series B Financing

Ambrogio Visconti North America, North America Legal Chronicle

Wilson Sonsini Goodrich & Rosati advised ONL Therapeutics, Inc. on the deal. ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Ambrogio Visconti

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here